Sign up for NeuroOne latest news and updates

NeuroOne is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures on our website www.pcgadvisory.com.

A growing opportunity for the neurology electrode market

Neurological conditions affect millions of Americans. In fact, 3.4 million people suffer from epilepsy alone. The portion of those who are surgical candidates have the potential to produce $5 billion in revenue from using electrode related technology. Similarly, 350,000 Americans currently suffer from brain tumors. Of those who are eligible to use electrodes in surgery, the potential revenue is estimated to be an additional $240 million.

Today’s current value for the brain electrode recording only market is $140 million, with experts estimating a CAGR of 4.5% between 2016 and 2025. In addition, NeuroOne’s platform technology is intended to address other markets such as Parkinson’s Disease, Pain due to failed back surgery(ies) and ablation of brain tissue for epilepsy and brain tumors, collectively representing a market opportunity already estimated to be over $2 billion worldwide. 

Patented technologies put in use with Mayo Clinic partnership

In order to capitalize on the market and address the unmet need of improved electrodes in treating neurological disorders, NeuroOne has developed patented technology that leverages printed circuit technology for minimally invasive treatments. The expectation for this scalable technology is to reduce both manufacturing and procedural costs while simultaneously improving patient outcomes.

The Mayo Clinic has partial ownership in NeuroOne and has assisted in the development process, successfully completing research milestones by using the company’s devices in humans. In addition, NeuroOne has licensed patents from Wisconsin Alumni Research Foundation, one of the oldest and most successful technology transfer offices in the nation.

Premarket success with FDA 510(k) approval

NeuroOne received its first FDA product clearance in 2019’s fourth quarter for its Evo™ cortical electrode product family. The Evo Cortical Electrode is a portfolio of thin film, high-definition strip and grid thin film electrodes that has 510(k)  clearance  to record, monitor and stimulation brain tissue for up to 30 days. It also features a disposable pre-sterilized cable assembly.

The company expects its second 510(k) submission in Q4 of 2020. It also has two additional products in development with another in the conceptualization phase. Together, the company’s portfolio of electrode technology has the potential to treat a broad range of neurological issues. There’s also potential for future use in artificial intelligence applications. 

An experienced team positions NeuroOne for long-term success

NeuroOne’s management team and strategic partners bring a wealth of expertise in both the medical device industry and in capital markets. The company’s growth trajectory is a result of the combined experience of a seasoned management team, board of directors, and two advisory boards focusing on neurological science and artificial intelligence.

Corporate milestones anticipate continued success through 2020

NeuroOne’s disruptive technology is ready to meet a significant unmet need that may offer substantially improved neurological outcomes along with lower costs. The company expects FDA 510(k) submission for its second product, and NeuroONe also plans to uplist to a national exchange by the end of the year.